The FDA has cleared Tonix Pharmaceuticals’ Investigational New Drug (IND) application to develop TNX-102 SL, a proprietary sublingual formulation of cyclobenzaprine HCl, to treat post-traumatic stress disorder (PTSD).

READ FULL ARTICLE Curated publisher From Pharmaceutical Business Review